TCGA-62-A470-01A-11R-A24H-07
— · cohortA3
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA3
- subtype
- cohortA3
- age_years
- 84
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.320
- FATTY_ACID_METABOLISM+0.230
- XENOBIOTIC_METABOLISM+0.220
- KRAS_SIGNALING_DN+0.180
- BILE_ACID_METABOLISM+0.160
- ADIPOGENESIS+0.140
- ESTROGEN_RESPONSE_LATE+0.090
- COAGULATION+0.060
- MYOGENESIS+0.010
- PEROXISOME+0.010
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.490
- MYC_TARGETS_V1-0.450
- INTERFERON_ALPHA_RESPONSE-0.440
- E2F_TARGETS-0.430
- INTERFERON_GAMMA_RESPONSE-0.430
- G2M_CHECKPOINT-0.420
- MITOTIC_SPINDLE-0.420
- APICAL_JUNCTION-0.380
- DNA_REPAIR-0.380
- MYC_TARGETS_V2-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12202450 | — | — | 0.880 |
| 2 | TCGA-NJ-A55R-01A-11R-A262-07 | — | cohortA3 | 0.875 |
| 3 | TCGA-62-A46P-01A-11R-A24H-07 | — | cohortA3 | 0.869 |
| 4 | TCGA-50-5051-01A-21R-1858-07 | — | cohortA3 | 0.862 |
| 5 | TCGA-55-A492-01A-11R-A24H-07 | — | cohortA2 | 0.862 |
| 6 | 3d1f44d8-6084-47cb-b57b-099f2cd1fa0e | — | — | 0.861 |
| 7 | TCGA-78-7149-01A-11R-2039-07 | — | cohortA2 | 0.854 |
| 8 | X32c1a1c5.08f3.4980.bdb3.37c652822988 | — | cohortA1 | 0.853 |
| 9 | SRR1324431 | GTEX | — | 0.848 |
| 10 | SRR1378004 | GTEX | — | 0.847 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.320 | Cobimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.220 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.180 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.140 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.090 | Idelalisib | — uncovered |
| COAGULATION | 0.060 | Binimetinib | — uncovered |
| MYOGENESIS | 0.010 | Inavolisib | — uncovered |
| PEROXISOME | 0.010 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.010 | Inavolisib | — uncovered |